177Lu-FAPI-FUSCC

N/A

Report date: 2025/09/15 17:34:13

NME

Base Information

Drug Name177Lu-FAPI-FUSCC

Drug Alias Name[177Lu]-FAPI-FUSCC

ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionFibroblast activation protein alpha modulators

TargetsProlyl endopeptidase FAP

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesFudan University Shanghai Cancer Center

China Registration ClassN/A

Develop Information

Active CompaniesFudan University Shanghai Cancer Center

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A